Clinical Trial Update: Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD). [Phase 3]

View source ↗

Summary

The document presents long-term safety findings from an open-label study of pramipexole extended-release in patients with early Parkinson disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Pramipexole ER (pramipexole)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Parkinson Disease | Phase 3 | Status: COMPLETED | Results posted: 2011-08-25